Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Analysis of Population Pharmacokinetic Data01:12

Analysis of Population Pharmacokinetic Data

244
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
244

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Diagnostic Delays in Thoracic Cancer Care: A Data-Linkage, Cohort Study between Primary Care, Hospital, and Registry Data.

Health data science·2026
Same author

Timeliness of Care and Treatment Patterns for Pancreatic Cancer in Victoria, Australia: Comparison With Optimal Care Pathways Targets.

ANZ journal of surgery·2026
Same author

Clinical Decision Support Tool for Early Pancreatic Cancer Detection in Primary Care: Simulation Study.

JMIR formative research·2026
Same author

Decision support tools for pancreatic cancer detection: external validation in Australian primary care - a retrospective cohort study.

The British journal of general practice : the journal of the Royal College of General Practitioners·2026
Same author

Time to diagnosis and treatment in lymphoma and implications for health-related outcomes: a systematic review.

Leukemia & lymphoma·2025
Same author

Evaluating a Clinical Decision Support Tool for Cancer Risk Assessment in Primary Care: Simulation Study of Unintended Weight Loss.

JMIR formative research·2025
Same journal

Adherence to international pharmacogenomic recommendations in pediatric cancer care: a cohort analysis embedded within the MARVEL-PIC randomized trial.

Pharmacogenomics·2026
Same journal

Closely similar tacrolimus morning troughs and graft function across the recipients' common <i>ABCB1</i> polymorphisms (<i>c.2677G>T/A</i>, <i>c.1236C>T</i>, <i>c.3435C>T</i>) early after renal transplantation.

Pharmacogenomics·2026
Same journal

Pharmacogenomics for stratified antidepressant treatment in major depressive disorder: evidence, limits and a roadmap for clinical use.

Pharmacogenomics·2026
Same journal

Guidance from an informed public on collecting and sharing PGx test results for major depressive disorder: "It's no different from your blood type".

Pharmacogenomics·2026
Same journal

Optimizing pharmacogenomics workflows: a qualitative evaluation of clinical service delivery models.

Pharmacogenomics·2026
Same journal

Combinations of single gene predictors with AI-driven polygenic precision therapies in cardiovascular diseases.

Pharmacogenomics·2026
See all related articles

Related Experiment Video

Updated: Jun 17, 2025

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry
05:53

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry

Published on: June 21, 2018

10.1K

Implementing pharmacogenomic testing in Australian general practice: an exploratory qualitative study.

Emma Ewasiuk1, Jon Emery2,3, Gabrielle Reid1

  • 1Department of Paediatrics, University of Melbourne, Melbourne, 3010, Australia.

Pharmacogenomics
|August 7, 2024
PubMed
Summary
This summary is machine-generated.

General practitioners (GPs) in Australia see potential in pharmacogenomic testing but face barriers like lack of education and guidelines. Successful implementation requires more evidence, standardized reports, and better financial accessibility.

Keywords:
consolidated framework for implementation researchgeneral practicegenetic testingimplementationpersonalized genomic medicinepharmacogenomics

More Related Videos

Pre-Implantation Genetic Testing for Aneuploidy on a Semiconductor Based Next-Generation Sequencing Platform
09:30

Pre-Implantation Genetic Testing for Aneuploidy on a Semiconductor Based Next-Generation Sequencing Platform

Published on: August 17, 2022

3.0K
Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer
06:21

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Published on: May 10, 2024

652

Related Experiment Videos

Last Updated: Jun 17, 2025

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry
05:53

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry

Published on: June 21, 2018

10.1K
Pre-Implantation Genetic Testing for Aneuploidy on a Semiconductor Based Next-Generation Sequencing Platform
09:30

Pre-Implantation Genetic Testing for Aneuploidy on a Semiconductor Based Next-Generation Sequencing Platform

Published on: August 17, 2022

3.0K
Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer
06:21

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Published on: May 10, 2024

652

Area of Science:

  • Pharmacogenomics
  • General Practice
  • Implementation Science

Background:

  • Pharmacogenomic testing offers personalized medicine potential.
  • Integration into Australian general practice requires understanding clinician perspectives.

Purpose of the Study:

  • To explore general practitioners' (GPs) views on implementing pharmacogenomic testing in Australian general practice.

Main Methods:

  • Semi-structured interviews with nine Australian GPs.
  • Thematic analysis of interview data.
  • Mapping themes to the Consolidated Framework for Implementation Research.

Main Results:

  • Key barriers identified: lack of knowledge, education, standardized reports, national guidelines, and financial constraints.
  • Facilitators include positive exposure, peer influence, interdisciplinary collaboration, and perceived clinical utility.
  • Current uptake is minimal, but GPs hold positive views on clinical application.

Conclusions:

  • Recommendations include disseminating clinical evidence and developing national guidelines and standardized reports.
  • Formal education and increased financial accessibility are crucial for successful implementation.
  • Addressing identified barriers and leveraging facilitators can promote pharmacogenomic testing adoption in general practice.